ADARx raised $446 million in an initial public offering, drawing attention to RNA interference as a validated drug modality. Investors have been selective since 2022, prioritizing companies with clear clinical catalysts, manufacturing plans, and adequate runway. RNAi leaders like Alnylam Pharmaceuticals and Arrowhead Pharmaceuticals have established delivery approaches such as GalNAc for liver targets, while extra-hepatic delivery remains a key milestone. A raise of this size can fund multi-year development and strengthen negotiating positions for partnerships. Higher interest rates have tightened access to capital, making disciplined spend and transparent milestones critical for public credibility. Founders in other sectors can apply the same timing and communication lessons to manage valuation and financing flexibility.
Learn more on this news by visiting us at: https://greyjournal.net/news/
","author_name":"GREY Journal"}